Multiple Sclerosis Medical Animation

CXCL1 Decreases Severity Of Multiple Sclerosis-like Disease
A group led by Dr. Cedric Raine at Albert Einstein College of Medicine have explored the expression of an immune molecule (CXCL1) that interacts with myelin-producing cells, finding that CXCL1 decreases the severity of disease in a mouse model of multiple sclerosis (MS). They report their data in the January 2009 issue of The American Journal of Pathology. The autoimmune disease multiple sclerosis (MS) attacks the central nervous system, resulting in demyelination of neurons.

Alnylam Publishes Pre-Clinical Research On Direct CNS Delivery Of RNAi Therapeutics
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has published data in the journal Oligonucleotides demonstrating robust silencing of an endogenous oligodendrocyte gene with small interfering RNAs (siRNAs), the molecules that mediate RNAi, when administered by direct delivery to the central nervous system (CNS) in both rats and non-human primates.

Teva Introduces New Thinner 29-Gauge Needle For COPAXONE® Pre-Filled Syringe
Teva (NASDAQ:TEVA) today announced the launch of a new, thinner, 29-gauge pre-filled syringe for its multiple sclerosis (MS) treatment, COPAXONE® (glatiramer acetate injection). A recent survey of 562 MS patients found the new thinner needle was significantly preferred by 77 percent of patients over the previous 27-gauge needle. "I used to hesitate before administering my daily injection because of slight discomfort experienced in the past," said Stacia D.

EUR 7 Million Grants Boost Trophos Cholesterol-oxime Programs For ALS, MS And Other Neurodegenerative Diseases
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics for indications with under-served needs in neurology and cardiology, announced that some EUR 7 million in funding has been awarded for two projects associated with its proprietary cholesterol-oxime class of compounds.

Cognition Pharmaceuticals Announces Positive Memory Results For Phase II Trial Of C105 In Multiple Sclerosis
Cognition Pharmaceuticals LLC announced positive results from a Phase 2 clinical trial of C105 (l amphetamine sulfate) on 151 Multiple Sclerosis patients with documented cognitive dysfunction. In the six-week placebo-controlled study, Cognition Pharmaceuticals reported, the active group obtained significantly higher scores on secondary outcome measures of memory and learning, including the Brief Visuospatial Memory Test - Revised, Total Recall (p = 0.

MRI Scans Can Predict Effects Of MS Flare-Ups On Optic Nerve
One of the most pernicious aspects of multiple sclerosis (MS) - its sheer unpredictability - may finally be starting to yield to advanced medical imaging techniques. Researchers from Washington University School of Medicine in St. Louis report online in the journal Neurology that an approach known as magnetic resonance diffusion tensor imaging (DTI) allowed them to estimate three months in advance the chronic effects of inflammation of the optic nerve.

The End Of A New Era? - Scientists In Mainz And Zürich Have Contested A Popular Hypothesis Concerning The Emergence Of Multiple Sclerosis (MS)
During an autoimmune disease, the endogenous defence system (the immune system) loses the ability to distinguish between "self" and "foreign". As a consequence, the immune system directs its defence against itself, with fatal consequences. In the case of multiple sclerosis, a chronic, inflammatory autoimmune disease, the immune system attacks the protective layer encapsulating the nerve fibres: This protective layer formed by myelin works like insulation for electrical cables.

Preventing A Recurrence Of The Northwick Park Trial
Scientists investigating the 2006 Northwick Park drug-trial disaster that left six healthy volunteers hospitalised say they have developed new pre-clinical tests that could have stopped the trial from ever going ahead. But Dr Stephen Poole, speaking at the British Pharmacological Society's Winter Meeting in Brighton, said that research is still "ongoing" to understand why the drug had such an adverse effect in the clinic but not in pre-clinical testing.

Royal Hospital For Neuro-disability And Channel 4 Highlight Ability In Disability, England
Next Wednesday, 17th December, the Royal Hospital for Neuro-disability features in Channel 4's Three Minute Wonder series. As part of the week-long strand themed Life After Coma, "Blah Blah Blah" focuses on Piotr, a remarkable resident living with Locked-in Syndrome, and shows how we have been able to restore his ability to communicate and publish three collections of poetry, despite his being over 90% paralysed.

IMPAX Provides Update On Meeting With FDA To Review Phase III Trial Results For IPX056
IMPAX Laboratories, Inc. announced that it met with representatives of the U.S. Food and Drug Administration (FDA) to review the results of its IPX056 clinical development program and discuss next steps in development leading to submission of a new drug application (NDA). IPX056 is an investigational extended-release formulation of baclofen, the drug of choice in the treatment of spasticity, which has the potential to offer improved control of symptoms and dosing convenience.

Multiple Sclerosis - FTY720 (Fingolimod) Trial Results
FTY720 (fingolimod), an experimental oral drug for relapsing MS is more effective than current treatments according to new research reported today. The trial, called TRANSFORMS, is the first of three studies of FTY720 to report. TRANSFORMS was a one year study involving 1,292 participants receiving either 0.5 mg or 1.25 mg FTY720 or interferon beta-1a (Avonex). During the study, people receiving interferon beta-1a experienced on average 0.33 relapses.

New Website For People With Multiple Sclerosis
MS Invigor8, a website developed by researchers at the University of Southampton, to treat fatigue in people with Multiple Sclerosis (MS) using Cognitive Behaviour Therapy (CBT) will be completed on Friday (12 December) and is ready to be trialled.

If MRI Shows Signs Of MS, Will The Disease Develop?
With more and more people having brain MRIs for various reasons, doctors are finding people whose scans show signs of multiple sclerosis (MS) even though they have no symptoms of the disease. A new study published in the December 10, 2008, online issue of Neurology®, the medical journal of the American Academy of Neurology, found that a third of these people developed MS within an average of about five years.

Sheffield Hallam University Seeks Early Diagnosis For MS
Sheffield Hallam University has begun a new three-year study which it hopes will lead to a test for early diagnosis of multiple sclerosis (MS). Early diagnosis means treatment can be started sooner, helping people with MS to remain active for longer.

MS Society Calls For Law Change On Unproven Stem Cell Trials
Following yesterday's published guidelines on unproven stem cell treatments by the International Society for Stem Cell Research (ISSCR), the MS Society is calling on the Government to change the law on advertising medicines. The MS Society supports the advice from the ISSCR that patients and their families should approach stem cell therapy with caution.